Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Hims & Hers had previously offered compounded versions of semaglutide -- the GLP-1 drug marketed as Ozempic and Wegovy -- which it and other compounding pharmacies were allowed to do legally ...

Hims & Hers took a hit when the Food and Drug Administration (FDA) announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply.

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though ...

In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's GLP-1 weight loss medications Ozempic and Wegovy. The offering was immensely popular and ...

The bank assigned a price target of $22 for Hims & Hers, implying a downside of around 25%. To demonstrate the value of its loss, compounded semaglutide drug sales brought in $225 million in ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...